Biogen and Eisai change agreements on Alzheimer's drug

An amendment to Biogen and Eisai’s partnership deal means the latter will start receiving royalties from Aduhelm sales next year. The companies have also decided to extend collaborations on a new Alzheimer’s treatment.


Going forward, Biogen and Eisai won’t be splitting global profits of Alzheimer’s drug Aduhelm (aducanumab), which is marketed in the US under the brand name Aduhelm, the companies announce in separate press releases.

Rather, Eisai will begin receiving tiered royalties based on net sales of the drug, which will take effect Jan. 1, 2023.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs